Top Testosterone Cypionate Brands to Boost Vitality

Testosterone cypionate is a popular medication used for hormone therapy, particularly in increasing levels of testosterone in men with low levels. With the growing demand for this treatment, various pharmaceutical brands have emerged, offering high-quality products to the market. Choosing the best brand is crucial for obtaining effective and reliable results, and many factors like purity, bioavailability, and cost can influence your decision. Below, we invite you to explore a curated list of top brands that stand out for their excellence in producing testosterone cypionate.

Illustration of testosterone cypionate

Best brands of testosterone cypionate in 2025

Pfizer

Pfizer is a leading producer of testosterone cypionate, with its DEPO-Testosterone Injection being a prominent product in the market. This injection is available in two strengths, 100 mg/mL and 200 mg/mL, and is widely used for testosterone replacement therapy, accounting for more than one-third of the testosterone replacement therapy revenue in 2022. The product's high adoption is due to its effectiveness and the slow absorption rate, allowing for injections at intervals of two to four weeks. Pfizer's dominance in the market is further highlighted by the clinics segment, which accounted for more than two-thirds of the testosterone replacement therapy revenue, often utilizing Pfizer's DEPO-Testosterone Injection. The global testosterone replacement therapy market, driven in part by Pfizer's products, is projected to reach $2.9 billion by 2032, growing at a CAGR of 4.2% from 2023 to 2032.

West-Ward Pharmaceuticals

West-Ward Pharmaceuticals is recognized for its high-quality production of testosterone cypionate, a crucial medication for treating hypogonadism and other conditions. The company's formulation is often preferred due to its reliability and consistency, with studies showing effective serum testosterone level adjustments within the normal male range, typically between 50 to 150 mg per dose. The product is available in various concentrations, such as 50-200mg/mL, and is administered via intramuscular or subcutaneous injection. West-Ward Pharmaceuticals ensures compliance with FDA standards, as evidenced by the rigorous clinical trials and safety evaluations conducted on their testosterone cypionate injections. This commitment to quality has made West-Ward Pharmaceuticals a trusted name in the pharmaceutical industry. For more information, please refer to their FDA product labeling.

Hikma Pharmaceuticals

Hikma Pharmaceuticals is a leading manufacturer of testosterone cypionate, known for its high-quality and reliable sterile injectable medicines. As of 2023, Hikma's US portfolio exceeds 150 injectable products, with a growth of over 50% in the last three years, solidifying its position as a top-three supplier of generic injectable medicines by volume in the US. The company's commitment to expanding its capabilities and product offerings has made it a trusted name in the healthcare system. Hikma's testosterone cypionate is part of a market forecasted to reach $302.7 million by 2030, growing at a CAGR of 6.8% from 2024 to 2030. This growth underscores Hikma's significant role in the global testosterone cypionate market.

Watson Pharmaceuticals

Watson Pharmaceuticals is recognized as a leading producer of testosterone cypionate, a crucial medication for testosterone replacement therapy. The company ensures high-quality formulations, with testosterone cypionate injection available in strengths of 100 mg/mL and 200 mg/mL, each containing specific excipients like benzyl benzoate and benzyl alcohol as preservatives. Testosterone cypionate from Watson Pharmaceuticals is administered intramuscularly, with a half-life of approximately eight days, allowing for dosing intervals of two to four weeks. The product is distributed under strict storage conditions, such as 20°-25°C (68°-77°F), to maintain its efficacy. Watson Pharmaceuticals' commitment to quality and compliance has made it a trusted name in the pharmaceutical industry. For more detailed information about testosterone cypionate from Watson Pharmaceuticals, visit their official documentation.

Teva Pharmaceuticals

Teva Pharmaceuticals, though primarily known as the largest generic drug manufacturer, does not specifically specialize in producing testosterone cypionate. However, the company's extensive portfolio and manufacturing capabilities make it a significant player in the pharmaceutical industry. Teva's revenues in 2023 reached $15.8 billion, reflecting a 7% increase in local currency terms compared to 2022, showcasing its financial strength and market presence. While Teva focuses more on generic drugs, branded products like Austedo and Ajovy are notable, but it does not highlight testosterone cypionate as one of its products. For testosterone cypionate, other companies like Xiromed LLC and Tolmar Pharmaceuticals are more directly involved in its production and distribution.

Sandoz

Sandoz, a renowned pharmaceutical company, is a significant producer of testosterone cypionate, a long-acting ester of testosterone used in testosterone replacement therapy. Testosterone cypionate, such as the brand Depo-Testosterone, is valued for its slow release and longer half-life of approximately eight days, making it convenient for patients with hypogonadism, who may require dosing every one to two weeks. In the market, testosterone cypionate segments, including those produced by Sandoz, have recorded substantial revenue shares, with the testosterone cypionate segment accounting for around 32.65% of the market in 2023. This medication is crucial for treating conditions like primary hypogonadism and hypogonadotropic hypogonadism, significantly improving symptoms such as libido, erectile function, and overall quality of life. The global testosterone replacement therapy market, which includes Sandoz's products, is expected to grow at a CAGR of 4.1% to reach $2.5 billion by 2031. For more information about testosterone cypionate, you can visit DrugBank's detailed entry.

Zydus Pharmaceuticals

Zydus Pharmaceuticals, a leading generic pharmaceutical company, is renowned for its high-quality testosterone cypionate products, which are FDA-approved and widely used to treat testosterone deficiency. As part of Zydus Lifesciences, the company has a global presence in 50 countries and is committed to improving patient health and wellness. Approximately 90% of prescriptions in the U.S. are filled with generic products, and Zydus Pharmaceuticals ensures that its generic medicines work identically to their brand-name counterparts, using the same active ingredients and offering the same benefits and risks. The company's dedication to saving and improving lives is reflected in its extensive product line, including testosterone cypionate, which is available in various formulations. Zydus Pharmaceuticals' products are developed to meet the highest standards, ensuring efficacy and safety for patients.

Sun Pharmaceutical Industries

Sun Pharmaceutical Industries, one of the world's leading generic pharmaceutical companies, is a prominent producer of testosterone cypionate injections. With global revenues of $5.4 billion and a presence in over 100 countries, Sun Pharma is known for its high-quality and affordable medicines. The company invests up to 6-8% of its global revenues in research and development, ensuring innovative and technologically complex products like testosterone cypionate injections. Sun Pharma's extensive manufacturing capabilities, including 43 facilities, support the production of a broad range of pharmaceutical formulations. However, the company has also faced recalls, such as the 2018 recall of over 5,200 units of testosterone cypionate injections due to the presence of particulate matter. For more information, you can visit their official website.

Mylan

Mylan, a prominent player in the pharmaceutical industry, is recognized for its high-quality production of testosterone cypionate, a crucial component in testosterone replacement therapy. The company's commitment to precision and efficacy has made its testosterone cypionate products a preferred choice among healthcare providers. In the North American market, Mylan's products have contributed significantly to the growth of the testosterone replacement therapy sector, which is expected to reach USD 0.98 billion by 2029, growing at a CAGR of 4.65% from 2024 to 2029. Mylan's involvement in this market is part of a broader trend where major pharmaceutical companies are focusing on developing economies and enhancing healthcare infrastructure. The increasing demand for testosterone replacement therapy, driven by rising awareness and government initiatives, further solidifies Mylan's position as a key producer in this field.

Cipla

Cipla, a global pharmaceutical company established in 1935, is a leading producer of testosterone cypionate, known for its commitment to agile and sustainable growth. Cipla has a strong presence in over 86 markets, including India, South Africa, and North America, and operates 47 manufacturing sites worldwide. The company is recognized for its innovative approaches, such as providing triple anti-retroviral therapy for HIV/AIDS at an affordable price, and it holds a significant market share in various therapeutic segments. Cipla's testosterone cypionate is part of its extensive product portfolio, which includes complex generics and drugs in multiple therapeutic areas. With a 5-year CAGR of 8%, Cipla continues to expand its market presence and product offerings. For more detailed information, you can refer to their Annual Report 2021-22.